Skip to main content

A specific and sensitive radioimmunoassay for rat C-peptide

Abstract

A sensitive and specific radioimmunoassay for rat serum C-peptide (RCP) has been developed and validated using a guinea pig anti-rat C-peptide antibody to synthetic rat C-peptide. Negligible crossreactivity (<0.01%) to human proinsulin was observed, whereas human insulin, human pancreatic polypeptide (hPP), porcine insulin, porcine C-peptide, bovine insulin, rat insulin, porcine-PP, and glucagon, respectively, did not produce measurable displacement of RCP tracer. Human C-peptide even in a supraphysiological concentration range crossreacted poorly (<0.1%). The sensitivity limit of the assay calculated at ±3 standard deviations was 24.2pM (0.07 ng/mL). RCP standard concentrations ranged from 25–1600pM. The intraassay-and between assay-coefficient of variations (CV) were 3.5–6.1% and 4.1–9.5%, respectively. The mean percentage recovery of RCP added to rat serum samples was 100.8±2%. Serum volume dilution from 25 to 100 μL did not significantly alter the expected RCP level. Migration of rat serum C-peptide and that of synthetic RCP were identical in a Sephadex G-50 chromatographic analysis. The mean fasting and postprandial plasma RCP levels in normal rats were 102±15pM and 485±75pM, respectively. RCP levels following intravenous glucose tolerance test in diabetic and nondiabetic rats were consistent with expected patterns.

In conclusion, we have developed and validated a rat C-peptide assay that is sensitive, simple, and specific for RCP in serum. The assay provides a reliable tool for studies of diabetes using rodent animal models.

This is a preview of subscription content, access via your institution.

References

  1. Ashby P, Frier BM. Circulating C-peptide: Measurement and clinical application.Am Clin Biochem 1981; 18: 125–130.

    CAS  Google Scholar 

  2. Bonser AM, Garcia-Webb P. C-peptide measurement: Methods and clinical utility, inCritical Reviews in Clinical Lab Sc 1984; 19(4): 297–352.

  3. Dryburgh JR, Hampton SM, Marks V. Endocrine pancreatic control of the release of gastric inhibitory polypeptide.Diabetologia 1980; 19: 397–401.

    PubMed  Article  CAS  Google Scholar 

  4. Flatt PR, Bailey CJ, Hampton SM, Swanston-Flatt SK, Marks V. Immunoreactive C-peptide in spontaneous syndromes of obesity and diabetes in mice.Horm Metabol Res 1987; 19: 1–5.

    Article  CAS  Google Scholar 

  5. Greenwood FC, Hunter WM, Glover JS. The preparation of 131-I-labeled human growth hormone of high specific radioactivity.Biochem J 1963; 89: 114–123.

    PubMed  CAS  Google Scholar 

  6. Heding LG, Larsen UD, Markussen J, Jorgensen KH, Hallund O. Radioimmunoassays for human, pork and ox C-peptides and related substances.Horm Metab Res Suppl 5: 1974; 5: 40–45.

    Google Scholar 

  7. Katz AL, Rubenstein AH. Metabolism of proinsulin insulin and C-peptide in the rat.J Clin Invest 1973; 52: 1113–1121.

    PubMed  Article  CAS  Google Scholar 

  8. Kuhl C, Faber OK, Hornnes P, Jensen SL. C-peptide metabolism and the liver.Diabetes 1978; 27 (Suppl 5): 197–200.

    PubMed  Google Scholar 

  9. Linde S, Nielsen JH, Hansen B, and Welinder BS. Reversed-phase high-performance liquid chromatographic analyses of insulin biosynthesis in isolated rat and mouse islets.J Chromatog 1989; 462: 243–249.

    Article  CAS  Google Scholar 

  10. Rubenstein AH, Block MB, Starr J, Melani F, Steiner DF. Proinsulin and C-peptide in blood.Diabetes 1972; 21(Suppl 2): 661–672.

    PubMed  CAS  Google Scholar 

  11. Sandler R, Horwitz DL, Rubenstein AH, Kuzuyah H. Hypoglycemia and endogenous hyperinsulinism complicating diabetes mellitus: Application of the C-peptide assay to diagnosis and therapy.Am J Med 1975; 59: 730–736.

    PubMed  Article  CAS  Google Scholar 

  12. Steiner DF. On the role of the proinsulin C-peptide.Diabetes 1978; 27(Suppl. 1): 145–148.

    PubMed  CAS  Google Scholar 

  13. Steiner DF, Hallund O, Rubenstein AH, Cho S, Bayliss C. Isolation and properties of proinsulin intermediate forms and other minor components from crystalline bovine insulin.Diabetes 1968; 17: 725–736.

    PubMed  CAS  Google Scholar 

  14. Wojcikowski C, Maier V, Dominiak K, Fussganger R, Pfeiffer EF. Effects of synthetic rat C-peptide in normal and diabetic rats.Diabetologia 1983; 25: 288–290.

    PubMed  Article  CAS  Google Scholar 

  15. Yanaihava C, Ozaki J, Nishida T, Iizuk Y, Sato H, Yanaihava H, Kaneko T. Immunological studies on synthetic rat and guinea pig C-peptides, inProinsulin and C-Peptide, Baba S, Kaneko T, Yanaihava V, eds. Excerpta Medica 1979; Amsterdam pp. 87–93.

  16. Yanaihava N, Yanaihava C, Sakagami M, Sakura N, Hashimoto T, Nishida T. Syntheses of C-peptides and human proinsulin.Diabetes 1978; 27(Suppl 1): 149–160.

    Google Scholar 

  17. Zettner A. Principles of competitive binding assays (saturation analyses). II. Sequential saturation.Clin Chem 1974; 20: 5–9.

    PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Akpan, J.O., Weide, L.G. & Gingerich, R.L. A specific and sensitive radioimmunoassay for rat C-peptide. International Journal of Pancreatology 13, 87–95 (1993). https://doi.org/10.1007/BF02786076

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02786076

Keywords

  • Pancreatology Volume
  • Gastric Inhibitory Polypeptide
  • Human Proinsulin
  • Beta Cell Activity